<?xml version="1.0" ?><ns2:com.thomson.ls.soa.stack.soaservices.service.contract.soap.v4.search.SearchOutput xmlns:ns2="local" id="666bab7e-6bd6-41e5-bd40-e90e78919b51" dataset="sourcesCorporatePublication" time="21"><serviceExecutionTime>32</serviceExecutionTime><lastDatasetUpdate>2019-02-16T00:12:36Z</lastDatasetUpdate><PagedResults total="81" firstRow="1" lastRow="50"><Result pos="1"><Field name="sourceId" type="string">220172</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Aztec, heprain (oral), Verex, insulin (oral), Verex</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-09-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Verex Laboratories Inc</Field></Result><Result pos="2"><Field name="sourceId" type="string">231901</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: CADDYS (growth hormone), Emisphere/Lilly, oral insulin, Emisphere, cromolyn, Emisphere, parathyroid hormone, Emisphere</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-01-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Emisphere Technologies Inc</Field></Result><Result pos="3"><Field name="sourceId" type="string">295420</Field><Field name="corporatePublicationTitle" type="string">Cortecs presents phase I oral insulin trial data at Controlled Release Symposium in Stockholm; Cortecs presents phase I oral insulin trial data at Controlled Release Symposium in Stockholm; Planning phase IIa European trial in 3rd quarter</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-08-20T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">PROVALIS Limited</Field></Result><Result pos="4"><Field name="sourceId" type="string">312999</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Insulin Sensizer, TPO agonists, EPO agonist, Growth Hormone Modulator, Leptin Modulator, Interleukin Modulators, by Receptron</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-01-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Receptron Inc</Field></Result><Result pos="5"><Field name="sourceId" type="string">337500</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: insulin (oral), Protein Delivery Inc</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-08-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Protein Delivery Inc</Field></Result><Result pos="6"><Field name="sourceId" type="string">357450</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: sucralfate, APCls, insulin analogs, NPC-16377, NPC-16570, NPC-18166, adipsin, heparin-EGF-like factor, cell adhesion inhibitors, bradykinin antagonists, KPI-022, BY-2001</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-02-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Scios Inc</Field></Result><Result pos="7"><Field name="sourceId" type="string">372335</Field><Field name="corporatePublicationTitle" type="string">Drug Development Pipeline - AERx (insulin)</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-06-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="8"><Field name="sourceId" type="string">371716</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: phosphorylated human insulin, Diabecore</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-06-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Diabecore Medical Inc</Field></Result><Result pos="9"><Field name="sourceId" type="string">400110</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: insulin glargine</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-02-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Aventis SA</Field></Result><Result pos="10"><Field name="sourceId" type="string">407391</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: insulin like growth factor receptor inhibitors</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-04-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Amgen Inc</Field></Result><Result pos="11"><Field name="sourceId" type="string">452854</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: insulin (oral), Nobex/GlaxoSmithKline</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-05-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">GlaxoSmithKline plc</Field></Result><Result pos="12"><Field name="sourceId" type="string">662549</Field><Field name="corporatePublicationTitle" type="string">Final Appraisal Determination - Long-acting insulin analogues for the treatment of diabetes – insulin glargine</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-10-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE</Field></Result><Result pos="13"><Field name="sourceId" type="string">492583</Field><Field name="corporatePublicationTitle" type="string">Novo Nordisk US - Insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-06-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="14"><Field name="sourceId" type="string">583719</Field><Field name="corporatePublicationTitle" type="string">An open label, single arm study to investigate the tolerance, pharmacokinetics and efficacy of a repeated dose of basulin - a new long-acting insulin - in 30 type 1 diabetic patients</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-02-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Flamel Technologies SA</Field></Result><Result pos="15"><Field name="sourceId" type="string">602297</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: BN-006, oral GCSF, oral insulin, Diabetology</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-05-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Diabetology Ltd</Field></Result><Result pos="16"><Field name="sourceId" type="string">606214</Field><Field name="corporatePublicationTitle" type="string">Novo Nordisk insulin product overview</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-06-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="17"><Field name="sourceId" type="string">989576</Field><Field name="corporatePublicationTitle" type="string">Clinical Trial Report: A Multinational, Randomized, Controlled, Open-labeled, Parallel Group Evaluation in Terms of Efficacy and Safety of Metformin 1700 mg/day Plus Twice Daily Biphasic Insulin Aspart 30 or Human NPH-insulin in Subjects with Type 2 Diabetes</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-10-19T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="18"><Field name="sourceId" type="string">681826</Field><Field name="corporatePublicationTitle" type="string">Pharmacodynamic Properties of VIAject: A Novel Rapid-Acting Regular Human Insulin</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-11-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biodel Inc</Field></Result><Result pos="19"><Field name="sourceId" type="string">662540</Field><Field name="corporatePublicationTitle" type="string">National Institute for Health and Clinical Excellence: Inhaled insulin for the treatment of diabetes (types 1 and 2) - Appraisal consultation document</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-04-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institute for Health and Clinical Excellence</Field></Result><Result pos="20"><Field name="sourceId" type="string">681825</Field><Field name="corporatePublicationTitle" type="string">Pharmacodynamics of VIAject: A Novel Rapid Acting Regular Human Insulin</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-06-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biodel Inc</Field></Result><Result pos="21"><Field name="sourceId" type="string">988483</Field><Field name="corporatePublicationTitle" type="string">Recombinant Human Pro-insulin C Peptide For Injection</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Newsummit Biopharma Co Ltd</Field></Result><Result pos="22"><Field name="sourceId" type="string">805671</Field><Field name="corporatePublicationTitle" type="string">A Randomised, Double-Blind, Placebo-Controlled Trial of Intranasal Insulin (40IU and 440IU) in Children and Young Adults at Risk of Type 1 Diabetes: Intranasal Insulin Trial II (INIT II)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-01-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Royal Melbourne Hospital</Field></Result><Result pos="23"><Field name="sourceId" type="string">765924</Field><Field name="corporatePublicationTitle" type="string">Delivery of Biologics - oral insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-02-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">MediVas LLC</Field></Result><Result pos="24"><Field name="sourceId" type="string">1488399</Field><Field name="corporatePublicationTitle" type="string">HTA Report - Short-acting Insulin Analogues for Diabetes Mellitus: Meta-analysis of Clinical Outcomes and Assessment of Cost-effectiveness</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-03-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Canadian Agency for Drugs and Technologies in Health (CADTH)</Field></Result><Result pos="25"><Field name="sourceId" type="string">903616</Field><Field name="corporatePublicationTitle" type="string">Product information: Emisphere's oral insulin program</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-04-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Emisphere Technologies Inc</Field></Result><Result pos="26"><Field name="sourceId" type="string">1487841</Field><Field name="corporatePublicationTitle" type="string">National Horizon Scanning - Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-12-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Health Service</Field></Result><Result pos="27"><Field name="sourceId" type="string">1060682</Field><Field name="corporatePublicationTitle" type="string">Early Communication About Safety of Lantus (insulin glargine)</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-07-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">FDA</Field></Result><Result pos="28"><Field name="sourceId" type="string">1075229</Field><Field name="corporatePublicationTitle" type="string">UPDATE: Discontinuation of Humulin 50/50 (50% Human Insulin Isophane Suspension and 50% Human Insulin Injection [rDNA Origin])</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Eli Lilly &amp; Co</Field></Result><Result pos="29"><Field name="sourceId" type="string">1073331</Field><Field name="corporatePublicationTitle" type="string">Biodel: Pipeline, BIOD- Smart Insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-02-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biodel Inc</Field></Result><Result pos="30"><Field name="sourceId" type="string">1075323</Field><Field name="corporatePublicationTitle" type="string">Novo Nordisk is discontinuing several insulin delivery devices</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-02-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="31"><Field name="sourceId" type="string">1080253</Field><Field name="corporatePublicationTitle" type="string">Insulin initiation in type 2 diabetes</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-03-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="32"><Field name="sourceId" type="string">1080209</Field><Field name="corporatePublicationTitle" type="string">Insulin Analogs</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-03-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">New England Healthcare Institute</Field></Result><Result pos="33"><Field name="sourceId" type="string">1080451</Field><Field name="corporatePublicationTitle" type="string">Drug datasheet: Humalog Mix75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection)</Field><Field name="corporatePublicationType" type="string">Drug Package Insert</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-03-09T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Eli Lilly &amp; Co</Field></Result><Result pos="34"><Field name="sourceId" type="string">1080450</Field><Field name="corporatePublicationTitle" type="string">Drug datasheet: Humalog (insulin lispro injection, USP (rDNA origin) 100 units per ml (U-100))</Field><Field name="corporatePublicationType" type="string">Drug Package Insert</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-03-09T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Eli Lilly &amp; Co</Field></Result><Result pos="35"><Field name="sourceId" type="string">1134041</Field><Field name="corporatePublicationTitle" type="string">Pharmacokinetics of novel formulations of insulin analogs providing a more rapid onset of action in the diabetic swine model</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-09-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biodel Inc</Field></Result><Result pos="36"><Field name="sourceId" type="string">1211351</Field><Field name="corporatePublicationTitle" type="string">Material safety data sheet : Insulin, Human</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Eli Lilly &amp; Co</Field></Result><Result pos="37"><Field name="sourceId" type="string">1215327</Field><Field name="corporatePublicationTitle" type="string">AFREZZA - A Novel Ultra Rapid-Acting Insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-08-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Mannkind Corp</Field></Result><Result pos="38"><Field name="sourceId" type="string">1485180</Field><Field name="corporatePublicationTitle" type="string">NN304-1938: A Multicenter, Open-label, Non-randomized, Non-interventional, Safety study in Patients With Type 2 Diabetes Treated With Insulin Detemir (Levemir)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-10-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="39"><Field name="sourceId" type="string">1544426</Field><Field name="corporatePublicationTitle" type="string">A randomized, open-label study of the effect of PEGASYS ® plus COPEGUS® with or without concomitant pioglitazone (Actos®) on early viral kinetics in treatment-naive patients with chronic hepatitis C, genotype-1, and insulin resistance</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="40"><Field name="sourceId" type="string">1514957</Field><Field name="corporatePublicationTitle" type="string">Treating Diabetes Using Menin Inhibitors to Regenerate Insulin Producing Beta Cells</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-02-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novapeutics LLc</Field></Result><Result pos="41"><Field name="sourceId" type="string">1290723</Field><Field name="corporatePublicationTitle" type="string">APC1 : a novel mechanism for treatment of diabetes type 2 Insulin Replacement Therapy</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-05-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">TwoToBiotech Ltd</Field></Result><Result pos="42"><Field name="sourceId" type="string">1308834</Field><Field name="corporatePublicationTitle" type="string">Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-06-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Orgenesis Inc</Field></Result><Result pos="43"><Field name="sourceId" type="string">1308836</Field><Field name="corporatePublicationTitle" type="string">Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-06-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Orgenesis Inc</Field></Result><Result pos="44"><Field name="sourceId" type="string">1491250</Field><Field name="corporatePublicationTitle" type="string">Novo Nordisk Briefing Document - FDA Endocrinologic and Metabolic Drug Advisory Committee - Insulin Degludec and Insulin Degludec/Insulin Aspart Treatment to Improve Glycemic Control in Patients with Diabetes Mellitus (NDAs 203314 and 203313)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-11-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="45"><Field name="sourceId" type="string">1487298</Field><Field name="corporatePublicationTitle" type="string">FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting - Briefing Document for Insulin Degludec and Insulin Degludec/Aspart</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-11-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="46"><Field name="sourceId" type="string">1513868</Field><Field name="corporatePublicationTitle" type="string">Multicenter, open, non-randomised controlled phase IV clinical trial of efficacy and safety for insulin glulisine injected subcutaneously in patients with type 1 diabetes mellitus using also insulin glargine</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="47"><Field name="sourceId" type="string">1355810</Field><Field name="corporatePublicationTitle" type="string">Ansulin - Insulin Human (rDNA) USP</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-01-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Square Pharmaceuticals Ltd</Field></Result><Result pos="48"><Field name="sourceId" type="string">1383932</Field><Field name="corporatePublicationTitle" type="string">FDA Application;  Results for Orphan Drug Product Designations Search: human insulin beta chain peptide with incomplete Freund's adjuvant vaccine; Treatment of Type 1 diabetes patients with residual beta cell function</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="49"><Field name="sourceId" type="string">1386159</Field><Field name="corporatePublicationTitle" type="string">Insulin SEDICO</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SEDICO Co</Field></Result><Result pos="50"><Field name="sourceId" type="string">1386153</Field><Field name="corporatePublicationTitle" type="string">Bioequivalance study of Insulin H Mix 100 IU Suspension</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SEDICO Co</Field></Result></PagedResults><DatasetCounts></DatasetCounts><HitTerms><Terms><Term>insulin</Term></Terms></HitTerms></ns2:com.thomson.ls.soa.stack.soaservices.service.contract.soap.v4.search.SearchOutput>